News + Filings Transactions Holdings
All
13F
13D/G
Other
|
|
ARCH Venture Fund VII, L.P.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2022 |
SC 13G/A
| ARCH Venture Fund VII, L.P. has filed a Schedule 13D for 908 Devices, Inc. |
| 02/04/2021 |
SC 13G
| ARCH Venture Fund VII, L.P. has filed a Schedule 13D for * 908 Devices Inc. |
| 02/02/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/22/2020 |
4
| ARCH Venture Fund VII, L.P. (10% Owner) has filed a Form 4 on 908 Devices Inc.|
Txns:
| Converted 5,425,045 shares
@ $0
Bought 300,000 shares
@ $20, valued at
$6M
Converted 2,927,386 preferred shares
@ $0
Converted 981,443 preferred shares
@ $0
Converted 669,977 preferred shares
@ $0
Converted 665,661 preferred shares
@ $0
Converted 180,578 preferred shares
@ $0 |
|
| 12/17/2020 |
3
| ARCH Venture Fund VII, L.P. (10% Owner) has filed a Form 3 on 908 Devices Inc. |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2020 |
SC 13G/A
| Arch Venture Fund VII LP reports a 21.9% stake in Unity Biotechnology, Inc. |
| 02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 07/25/2019 |
SC 13D/A
| Arch Venture Fund VII LP has filed a Schedule 13D for Pulmatrix, Inc. |
| 07/17/2019 |
4
| ARCH Venture Fund VII, L.P. (10% Owner) has filed a Form 4 on Syros Pharmaceuticals, Inc.|
Txns:
| Sold 2,700 shares
@ $8.2651, valued at
$22.3k
Sold 25,779 shares
@ $7.8078, valued at
$201.3k
Sold 34,521 shares
@ $7.6964, valued at
$265.7k
|
|
| 03/22/2019 |
SC 13D/A
| Arch Venture Fund VII LP reports a 5.6% stake in Pulmatrix, Inc. |
| 03/14/2019 |
4
| ARCH Venture Fund VII, L.P. (10% Owner) has filed a Form 4 on Syros Pharmaceuticals, Inc.|
Txns:
| Sold 40,092 shares
@ $7.3674, valued at
$295.4k
Sold 81,591 shares
@ $7.8862, valued at
$643.4k
Sold 2,820 shares
@ $8.1993, valued at
$23.1k
Sold 43,000 shares
@ $8.1498, valued at
$350.4k
|
|
| 03/11/2019 |
4
| ARCH Venture Fund VII, L.P. (10% Owner) has filed a Form 4 on Syros Pharmaceuticals, Inc.|
Txns:
| Sold 35,209 shares
@ $6.8736, valued at
$242k
Sold 84,496 shares
@ $6.9266, valued at
$585.3k
Sold 44,878 shares
@ $6.4924, valued at
$291.4k
|
|
| 02/14/2019 |
SC 13G
| Arch Venture Fund VII LP reports a 23.7% stake in Unity Biotechnology, Inc. |
| 02/14/2019 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/14/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/06/2018 |
4
| ARCH Venture Partners VIII, LLC (10% Owner) has filed a Form 4 on Twist Bioscience Corp|
Txns:
| Converted 1,182,645 shares
@ $0
Converted 718,275 shares
@ $0
Converted 266,776 shares
@ $0
Converted 224,726 shares
@ $0
Bought 15,000 shares
@ $14, valued at
$210k
Converted 894,146 shares
@ $0
Bought 60,000 shares
@ $14, valued at
$840k
Converted 1,182,645 preferred shares
@ $0
Converted 718,275 preferred shares
@ $0
Converted 266,776 preferred shares
@ $0
Converted 224,726 preferred shares
@ $0 |
|
| 10/30/2018 |
3
| ARCH Venture Partners VIII, LLC (10% Owner) has filed a Form 3 on Twist Bioscience Corp |
| 05/07/2018 |
4
| ARCH Venture Partners VII, LLC (10% Owner) has filed a Form 4 on Unity Biotechnology, Inc.|
Txns:
| Converted 2,030,625 shares
@ $0
Converted 4,228,432 shares
@ $0
Converted 2,067,160 shares
@ $0
Converted 1,486,745 shares
@ $0
Converted 195,672 shares
@ $0
Converted 2,030,625 preferred shares
@ $0
Converted 4,228,432 preferred shares
@ $0
Converted 2,067,160 preferred shares
@ $0
Converted 1,486,745 preferred shares
@ $0
Converted 195,672 preferred shares
@ $0 |
|
| 05/03/2018 |
3
| ARCH Venture Partners VII, LLC (10% Owner) has filed a Form 3 on Unity Biotechnology, Inc. |
| 04/12/2018 |
4
| Arch Venture Fund VII LP (Former 10% Owner) has filed a Form 4 on Pulmatrix, Inc. |
| 04/12/2018 |
SC 13D/A
| Arch Venture Fund VII LP reports a 9.9% stake in Pulmatrix, Inc. |
| 04/05/2018 |
4
| GILLIS STEVEN (Director) has filed a Form 4 on Pulmatrix, Inc.|
Txns:
| Bought 1,150,000 shares
@ $0
Bought 1,150,000 options to buy
@ $0.65, valued at
$747.5k
Bought 1,150,000 options to buy
@ $0.75, valued at
$862.5k
|
|
| 03/09/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2018 |
SC 13G/A
| Arch Venture Fund VII LP reports a 17.7% stake in Syros Pharmaceuticals, Inc. |
| 02/02/2018 |
SC 13G/A
| Arch Venture Fund VII LP reports a 9.3% stake in Juno Therapeutics, Inc. |
| 01/05/2018 |
SC 13D/A
| Arch Venture Fund VII LP reports a 10.9% stake in Pulmatrix, Inc. |
| 02/14/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/13/2017 |
SC 13G/A
| Juno Therapeutics, Inc. reports a 10% stake in Juno Therapeutics, Inc. |
| 02/13/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals [Amend] |
|
|
|